Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
1. SRPT reported Q1 losses of $3.42 per share, exceeding analyst estimates. 2. Quarterly revenue was $744.86 million, surpassing estimates of $683.36 million. 3. Company adjusted 2025 revenue guidance to $2.3-$2.6 billion due to challenges. 4. Analysts lowered price targets post earnings announcement; mixed ratings remain. 5. Shares plummeted 26.6% following the earnings report, closing at $46.75.